Lower Extremity Invasive Diagnostic and Endovascular Procedures
Customize your policy alerts
Sign up for longevityhealthplanofcolorado Policy UM.043 alerts
Get alerted when Policy UM.043 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical necessity criteria for lower extremity peripheral artery revascularization services (endovascular procedures including PTA and stenting) for members of Longevity Health Plan of Colorado. It supplements and reiterates NCD 20.7 and LCD L35998 guidance.
No material clinical or coverage changes in this revision.
Coverage Criteria for PTA and Stenting
inv-01: Covered Indications for PTA and Stenting
Covered when ALL of the following conditions are met:
Based on L35998 and NCD 20.7 guidance; documentation required in the medical record.
inv-02: Arterial-specific appropriateness criteria
Covered/appropriate, may-be-considered, and rarely-appropriate indications are described by arterial territory.
inv-03: Coverage for lower extremity ischemia
Endovascular revascularization procedures are considered medically necessary when ALL of the following are met:
Documentation of imaging and prior conservative therapy required for prior authorization.
inv-04: Coverage for chronic limb-threatening ischemia (CLTI)
Chronic limb-threatening ischemia (CLTI) is covered when ALL of the following are met:
Documentation of objective ischemia and imaging required.
inv-05: Claudication — angioplasty criteria
Treatment of claudication — angioplasty is considered medically necessary when ALL of the following are met:
See anatomic criteria for lesion-specific requirements.
Lesion-specific lengths required for coverage.
inv-06: Claudication — stent placement
Claudication — primary stent placement is considered medically necessary when ALL of the following are met:
Covered stent devices may be medically necessary for aortoiliac disease with severe calcification or aneurysmal change.
inv-07: Salvage therapy criteria
Salvage (provisional) therapy after angioplasty is considered medically necessary when ANY of the following are present:
Applies when residual stenosis/complication occurs after angioplasty in femoral, popliteal, or tibial arteries.
inv-08: Critical Limb Ischemia coverage
For individuals with limb-threatening critical limb ischemia (CLI) due to lower extremity occlusive arterial disease, endovascular procedures are considered medically necessary when the following top-level clinical condition is present:
Documentation of ischemic signs and imaging of occlusive disease required.
This policy incorporates and summarizes the language of LCD L35998. For states where no active Local Coverage Determination (LCD) exists, Longevity Health Plan of Colorado adopts the L35998 language to provide guidance. The LCD describes the general role of vascular stents — to enhance primary patency at stenotic or occlusive lesions or as an adjunct when percutaneous transluminal angioplasty (PTA) alone is unlikely to produce a durable result — and frames the conditions under which PTA and stenting are covered by the Plan.
Renal artery stenting is identified as rarely appropriate in specific clinical situations. Examples include renal artery stenosis when blood pressure is controlled and renal function is normal; when the affected kidney measures 7 cm pole-to-pole; in patients with chronic end-stage renal disease on hemodialysis for > 3 months; and for chronic total occlusion of the renal artery. These circumstances generally indicate that stenting is unlikely to provide meaningful clinical benefit and therefore is not routinely supported.
The placement of a stent in a vessel without an objective symptom or functional limitation is considered preventive and is not covered. Consistent with Medicare guidance summarized from L35998, stent placement intended solely to prevent future progression in an asymptomatic patient or to treat an otherwise nonviable limb is not a covered service.
PTA and stenting are covered only when all specified conditions in this policy are met. Coverage requires documented prior medical evaluation and management, consideration of surgery as an alternative, and procedural justification when a stent is planned as a primary adjunct because PTA alone is unlikely to achieve a durable result. Providers must meet these prerequisites and provide the required documentation to support medical necessity.
The policy states that renal artery stenting is generally not indicated for a number of listed situations. Specifically, stenting is rarely appropriate when blood pressure is controlled with normal renal function, when renal size is 7 cm, in patients with chronic end-stage renal disease on dialysis > 3 months, and for chronic total occlusion. These examples reflect scenarios where the expected clinical benefit from revascularization is low.
Based on the evidence summarized in the policy, endovascular revascularization (including stents, angioplasty, and atherectomy) is considered not medically necessary and unproven for isolated infrapopliteal claudication. The policy specifically identifies claudication caused solely by anterior tibial, posterior tibial, or peroneal artery disease as an indication where these interventions are not supported.
Referenced Codes and Clinical Thresholds
| L35998 | Non-Coronary Vascular Stents (LCD reference) |
| NCD 20.7 | Percutaneous Transluminal Angioplasty (NCD reference) |
| No codes listed |
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required
Prior authorization is required for lower extremity peripheral artery revascularization services.
Prior authorization: rationale and supporting clinical data
Include documented clinical indication and rationale for PTA/stenting when requesting prior authorization, with detailed justification for infra‑popliteal stent placement or renal artery stenting where specific clinical scenarios apply.
- Justify infra‑popliteal stent placement in the medical record (rationale must be thoroughly explained).
- For renal artery stenting, document indication (e.g., dissection, aneurysm, or atherosclerosis >50% in a transplanted kidney) and supporting clinical scenario (flash pulmonary edema/ACS with severe HTN; resistant HTN despite ≥3 agents including a diuretic; or ischemic nephropathy with eGFR <45 and global renal ischemia).
Prior authorization expectation — imaging and conservative therapy
Prior authorization is expected to include objective imaging demonstrating anatomic location and severity of stenosis and documentation that required conservative therapies were tried and failed before endovascular revascularization for claudication or CLTI.
- If duplex ultrasound does not show ≥50% stenosis, submit alternative imaging (CTA, MRA, or invasive angiography).
- Confirm failure of conservative therapies (including supervised/structured exercise program ≥12 weeks and pharmacologic therapy) when applicable.
Medical management prerequisite
Document evidence that the patient has undergone prior thorough medical evaluation and management of symptoms before PTA or stenting will be covered.
- Medical record should reflect prior evaluation and management steps taken specific to the patient’s presentation.
Medication therapy failure before renal stenting
For resistant hypertension being considered for renal artery stenting, document failure of maximally tolerated doses of at least three antihypertensive agents, one of which is a diuretic.
- Include medication names, doses, duration, and any intolerance or contraindications noted.
Required conservative therapy before intervention
Prior to intervention for claudication, document that conservative stepwise care was tried and failed, including at least 12 weeks of a supervised or structured exercise program and appropriate pharmacologic therapy.
- Record duration and participation in the supervised/structured exercise program (minimum 12 weeks).
- Document pharmacologic therapy used (e.g., antiplatelet agents, cilostazol) and response or contraindications.
Medical management documentation
Include documentation that the patient has undergone prior thorough medical evaluation and management of symptoms in the medical record as a prerequisite for coverage of PTA and stenting.
- Specify prior evaluations, medical therapies, and their outcomes relevant to the current request.
Alternative treatment documentation
Document that surgical intervention would be considered an alternative treatment option for the patient when submitting records supporting endovascular therapy.
- Note whether surgery is a viable alternative and clinical factors influencing that decision.
Document rationale for infra-popliteal stenting
When stent placement is performed in infra‑popliteal vessels, thoroughly explain the clinical rationale for stent placement in the medical record.
- Describe why stenting is necessary versus angioplasty alone and document lesion characteristics that support stent use.
Document renal artery indications
For renal artery stenting, document the specific indication and supporting clinical circumstances such as flash pulmonary edema/ACS with severe hypertension, resistant hypertension despite ≥3 agents including a diuretic, or ischemic nephropathy with eGFR <45 and global renal ischemia.
- Specify whether indication is dissection, aneurysm, or atherosclerosis >50% (including transplanted kidney).
- Provide relevant clinical data (e.g., eGFR, episodes of flash pulmonary edema, medication history).
Required documentation — imaging and physiologic testing
Provide imaging that shows anatomic location and severity of occlusion (stenosis ≥50%) and include physiologic testing or ischemic measurements where applicable (ABI, ankle/toe pressures, TBI, TcPO2).
- Acceptable imaging: duplex ultrasound, CTA, MRA, or invasive angiography; if duplex is nondiagnostic for ≥50% stenosis, submit alternate imaging.
- Document ABI (≤0.69), ankle pressure (<50 mmHg), TBI (≤0.70), toe pressure (<30 mmHg), or TcPO2 (<25 mmHg) when CLTI is claimed.
Prior authorization requirement — denial risk
Failure to obtain prior authorization for lower extremity peripheral artery revascularization services may lead to denial of coverage.
Documentation risk for infra-popliteal stents
Because infra‑popliteal stent placement is expected to be uncommon, lack of a thorough explanation and rationale in the record for infra‑popliteal stenting may trigger denial.
Denial triggers — missing therapies or documentation
Procedures may be denied if required conservative therapies have not been tried and failed or if objective testing does not demonstrate the required anatomic or physiologic thresholds (e.g., stenosis ≥50% or ABI/TBI/pressure/TcPO2 thresholds).
- Conservative therapies include supervised/structured exercise program (≥12 weeks), pharmacologic therapy, and smoking cessation when applicable.
- Objective thresholds: stenosis ≥50% on imaging; ABI ≤0.69; ankle pressure <50 mmHg; TBI ≤0.70; toe pressure <30 mmHg; TcPO2 <25 mmHg.
Background and Scope
Peripheral artery disease (PAD) is a chronic atherosclerotic condition that reduces extremity blood flow and produces a spectrum of clinical presentations from exertional claudication — exercise-induced muscle pain relieved by rest — to chronic limb‑threatening ischemia (CLTI), characterized by rest pain, nonhealing ischemic ulcers, gangrene, or impending limb loss. Endovascular therapies such as PTA, atherectomy, and stenting are used to restore perfusion and may be appropriate for symptomatic patients who meet the policy’s clinical, functional, and objective imaging criteria; conversely, interventions are not supported for asymptomatic individuals, to prevent progression of claudication, or for isolated infrapopliteal claudication where evidence of benefit is insufficient.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.